295 related articles for article (PubMed ID: 34390854)
1. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma.
Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q
Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854
[TBL] [Abstract][Full Text] [Related]
2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Biomarker ZNF311 and Its Correlation With Tumor Progression and Immune Infiltrates in Glioma.
Ge X; Jiang S; Wang Z; Hu N; Jiang R; Cai Z; Wu B; Zhang Y; Gong P
World Neurosurg; 2021 Jul; 151():e37-e46. PubMed ID: 33746099
[TBL] [Abstract][Full Text] [Related]
4. [Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
Chen Y; Li Q; Zhang J; Gu R; Li K; Zhao G; Yuan H; Feng T; Ou D; Lin P
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2020 Jun; 37(3):469-479. PubMed ID: 32597089
[TBL] [Abstract][Full Text] [Related]
5.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
6. RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
Jin X; Xie H; Liu X; Shen Q; Wang Z; Hao H; Gu Y
Int Immunopharmacol; 2020 Oct; 87():106707. PubMed ID: 32683297
[TBL] [Abstract][Full Text] [Related]
7. COMMD4 is a novel prognostic biomarker and relates to potential drug resistance mechanism in glioma.
Liu Z; Peng L; Sun Y; Lu Z; Wu B; Wang W; Zhang X; Hao H; Gong P
Front Pharmacol; 2022; 13():974107. PubMed ID: 36249824
[No Abstract] [Full Text] [Related]
8. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
9. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
10. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
11. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
12. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
13. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
14. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Role of Glutathione Peroxidase 1 and Immune Infiltrates in Glioma Investigated Using Public Datasets.
Lv S; Luo H; Huang K; Zhu X
Med Sci Monit; 2020 Oct; 26():e926440. PubMed ID: 33085656
[TBL] [Abstract][Full Text] [Related]
16. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
17. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
19. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
Zhu J; Lin Q; Zheng H; Rao Y; Ji T
Front Oncol; 2022; 12():897042. PubMed ID: 36505882
[TBL] [Abstract][Full Text] [Related]
20. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
